Array Expanding Capabilities, Runs First Phase III Trial

Orelli, Brian
May 2013
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p3
The article informs that pharmaceutical company Array BioPharma Inc. is starting its first Phase III clinical trial for Mitogen-activated, Extracellular signal–regulated Kinase (MEK) 162. It states that the trial named MEK Inhibitor in Low Grade Serous Ovarian Cancer (MILO) will compare MEK162 with standard chemotherapy treatments in patients with recurrent low-grade ovarian cancer. It also states that partial cost of the trial will be borne by Basel, Switzerland-based firm Novartis AG.


Related Articles

  • Ovarian Trial 'MEKs' Big Year: Array Rolls Out Five Phase IIIs. Osborne, Randy // BioWorld Today;5/8/2013, Vol. 24 Issue 88, p1 

    This article discusses the Array BioPharma Incorporated's Phase III trial in recurrent low-grade serous ovarian cancer with its Novartis AG-partnered methyl ethyl ketone (MEK) inhibitor to be performed in 2013. The ovarian cancer trial, MEK Inhibitor in Low Grade Serous Ovarian Cancer, will test...

  • Only the 'Beginning of the Story'. Osborne, Randy // BioWorld Today;5/8/2013, Vol. 24 Issue 88, p3 

    This article presents information on the MEK162 product that is designed to inhibit methyl ethyl ketone (MEK), a key protein in various pathways that signal cancer cell proliferation and survival. The drug was licensed by Novartis in 2010 when Array Biopharma Incorporated provided an advance of...

  • AACR 2012.  // BioWorld Today;4/5/2012, Vol. 23 Issue 66, p3 

    The article reports on the results of the Phase II trial of Array BioPharma Inc. for selumetinib, a small-molecule MEK inhibitor, among women with recurrent low-grade serous ovarian or peritoneal cancer.

  • Array, Novartis Ink MEK Deal Worth up to $467M.  // Bioworld Week;4/26/2010, Vol. 18 Issue 17, p1 

    The article reports that Array BioPharma has obtained a deal with Novartis AG worth 467 million dollars for its MEK inhibitors. Array's chief financial officer Mike Carruthers has revealed that the deal requires Novartis to put up 45 million dollars in cash and 422 million in milestones. It adds...

  • Array BioPharma Achieves $10 Mln Clinical Milestone in MEK162 Oncology Program.  // Biomedical Market Newsletter;5/14/2011, p797 

    The article informs that Array BioPharma Inc. has achieved a 10mn dollars clinical research milestone, in collaboration with Novartis AG. In April 2010, Array signed an agreement with Novartis, for the development of small-molecule MEK (methyl ethyl ketone) inhibitors MEK162 (ARRY-162), its...

  • Anything but 'TDM' in San Antonio.  // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p5 

    The article reports on the positive interim results of the Phase I trial of ARRY-380, a small molecule HER2 (Human Epidermal Growth Factor Receptor 2) (ErbB2) inhibitor, in advanced cancer patients. The Phase I trial of the drug from Array BioPharma Inc. has revealed that the drug at doses...

  • Array BioPharma files IND application for Phase I cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p11 

    The article reports on the filling of an investigational new drug (IND) application by biopharmaceutical company Array BioPharma Inc. to the U.S. Food and Drug Administration (FDA). The purpose of the IND is for the initiation of a Phase I clinical trial in cancer patients with the use of the...

  • 'Array' of Hope in RA Phase II, but MEK Inhibitor Still Fizzles. Osborne, Randy // BioWorld Today;9/8/2009, Vol. 20 Issue 172, p1 

    The article reports that Array Biopharma Inc. is open for partnership for the Phase II trial of its ARRY-162 in rheumatoid arthritis (RA). According to chief executive officer (CEO) Robert E. Conway, they are not sure if many would be interested with RA. On the other hand, the company will...

  • Array BioPharma anticancer compound cleared to advance into human clinical trials.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p6 

    Reports that Array BioPharma Inc.'s anticancer compound, ARRAY-142886 has been cleared by the U.S. Food and Drug Administration to advance into human clinical trials. Administration of ARRAY-142886 in certain preclinical skin, pancreatic, colon, lung and breast tumor models resulted in tumor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics